Intradermal tranexamic acid and melasma: a systematic review and level of evidence - PubMed

4 hours ago

Intradermal tranexamic acid (ID TXA) is a well-tolerated and effective treatment for melasma, with varying concentrations offering different efficacy and safety profiles.
ID TXA at 4 mg/mL significantly improves melasma severity, often comparable to or better than hydroquinone 4% or laser therapy, with mild and transient side effects.
ID TXA at 100 mg/mL shows similar or superior efficacy to hydroquinone and oral TXA, with a lower recurrence rate than laser therapy.
Melasma is a common pigmentary disorder affecting sun-exposed areas like the face and neck, impacting quality of life due to cosmetic and psychological concerns.

Hasty Briefsbeta